By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Arbutus Biopharma (Formerly Known As Tekmira Pharmaceuticals Corporation) 

3805 Old Easton Road
Doylestown, PA 18902

8900 Glenlyon Parkway

Burnaby,  British Columbia,  V5J 5J8  Canada
Phone: 604-419-3200 Fax: 604-419-3201


Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

In addition to our HBV Assets, we are developing a pipeline of oncology, anti-viral and metabolic programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.

Key Statistics

Ownership: Public

Web Site: Arbutus Biopharma
Employees: <500 Employees
Symbol: ABUS

Company News
Arbutus Biopharma (ABUS) To Participate In Upcoming Investor Conferences 2/4/2016 2:35:05 PM
Arbutus Biopharma (ABUS) Provides A Corporate Update And Outlines 2016 Milestones 1/11/2016 8:25:56 AM
Arbutus Biopharma (ABUS) Provides An HBV Pipeline Update 10/28/2015 7:10:24 AM
NeuroVive (NVP)'s OCB-030 Preclinical Program Has Been Discontinued By Arbutus Biopharma (ABUS) 10/28/2015 6:42:34 AM
Dr. Michael J. Sofia, Arbutus Biopharma (ABUS)' Chief Scientific Officer, Named Economist's 2015 Innovation Award Winner In The Bioscience Category 10/15/2015 7:52:11 AM
Arbutus Biopharma (ABUS) Presents Preclinical Data At The 2015 International Meeting On Molecular Biology Of Hepatitis B Viruses 10/6/2015 8:07:22 AM
Arbutus Biopharma (ABUS) To Present TKM-HBV Data At The 2015 American Association for Study of Liver Diseases Liver Meeting 10/1/2015 10:29:53 AM
Arbutus Biopharma (ABUS) To Present At The Baird 2015 Healthcare Conference 9/10/2015 10:58:47 AM
Arbutus Biopharma (ABUS) Announces Initiation Of Patient Dosing In The TKM-PLK1 HCC Expansion Cohort 8/25/2015 7:09:09 AM
Arbutus Biopharma (ABUS) To Present At 2015 Wedbush PacGrow Healthcare Conference 8/7/2015 12:31:14 PM